Skip to main content

NRX Pharmaceuticals, Inc.

For the period ended Dec 17, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Dec 17, 2026 · Filed Nov 5, 2026

NRXP$2.38+4.8%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Pay Versus Performance Table

The following table shows the past three fiscal years’ total compensation for our Named Executive Officers as set forth in the Summary Compensation Table (“SCT”), the CAP to our Named Executive Officers (as determined pursuant to SEC rules), our total stockholder return (“TSR”), and our net loss. We are a “smaller reporting company,” as defined in Rule 12b-2 under the Exchange Act, and have elected to provide in this Proxy Statement certain scaled disclosures permitted under the Exchange Act for smaller reporting companies.

SEC rules require certain adjustments be made to the SCT totals to determine CAP as reported in the pay versus performance table. CAP does not necessarily represent cash and/or equity value transferred to the applicable Named Executive Officer without restriction, but rather is a valuation calculated under applicable SEC rules. The methodology for calculating CAP as required by Item 402(v) of Regulation S-K takes into account, among others, changes in share price and its impact on the fair value of equity awards.

YearSCT Total for PEO (1)CAP to PEO (2)Average SCT Total for Non-PEO NEOs(3)Average CAP to Non-PEO NEOs(4)Value of initial fixed $100 investment based on TSR(5)Net Income (Loss) ($000)
2025$884,701$1,042,201$1,077,566$1,252,613$244,14$(28,622)
2024$789,583$789,583$1,221,596$1,221,596$198.20$(25,126)
2023$500,000$(150,000)$857,770$900,770$414.41$(30,150)
(1)Represents to total compensation reported for Jonathan Javitt. Dr. Javitt served as our Interim Chief Executive Officer starting October 7, 2024 and served as our Chief Executive Officer starting January 4, 2026.
(2)The dollar amounts reported represent the amount of CAP as computed in accordance with SEC rules. The dollar amounts reported are the amounts of total compensation reported for each PEO during the applicable year, but also include the year-end value of equity awards granted during the reported year. See Table below for further information.
(3)The dollar amounts reported are the average of the total compensation reported for our NEOs, other than our PEOs (“NON-PEO NEOs”). For fiscal year 2025, our NON-PEO NEOS were Michael Abrams and Michael Duffy. For fiscal year 2024, our NON-PEO NEOS were Jonathan Javitt, Stephen H. Willard, Richard Narido, Michael Abrams, and Matthew Duffy. For fiscal year 2023, our NON-PEO NEOS was Richard Narido.
(4)The dollar amounts reported represent the average amount of CAP, as computed in accordance with SEC rules, for our NEOs, other than our PEOs. The dollar amounts reported are the average of the total compensation reported for our NEOs, other than our PEOs, in the SCT for fiscal years 2025, 2024, and 2023, but also include the year-end value of equity awards granted during the reported year. See Table below for further information.
(5)Assumes an investment of $100 for the period starting on December 31, 2022 through the end of the listed fiscal year. The closing prices of the Company’s common stock as reported on Nasdaq, as applicable, on the following trading days were: (i) $1.11 on December 30, 2022; (ii) $4.60 on December 31, 2023, (iii) $2.20 on December 31, 2024, and (iv) $2.71 on December 31, 2025.

The table below summarizes the adjustments to the total amount reported in the SCT for PEO 1 in calculating CAP:

Year · SCT Total for PEO 1 · Reported Value of Equity Awards for PEO 1(1) · Fair Value as of Year End for Unvested Awards Granted During the Year · Fair Value Year over Year Increase or Decrease in Unvested Awards Granted in Prior Years · Fair Value of Awards Granted and Vested During the Year · Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year · CAP to PEO 1
2025$884,701$(166,250)$323,750$-$-$-$1,042,201
2024$789,583$-$-$-$-$-$789,583
2023500,000--$(433,329)$(216,671)$(150,000)
(1)Represents the grant date fair value of the equity awards to PEO, as reported in the SCT.

The table below summarizes the adjustments to the average of the total amount reported in the SCT for our NEOs other than our PEOs in calculating CAP:

Year · Average SCT Total for Non-PEO NEOs · Average Reported Value of Equity Awards for Non-PEO NEOs(1) · Average Fair Value as of Year End for Unvested Awards Granted During the Year · Average Fair Value Year over Year Increase or Decrease in Unvested Awards Granted in Prior Years · Average Fair Value of Awards Granted and Vested During the Year · Average Fair Value Increase or Decrease from Prior Year end for Awards that Vested during the Year · Average CAP to Non- PEO NEOs
2025$1,077,566$(276,175)$451,222$-$-$-$1,252,613
2024$1,221,596$-$-$-$-$-$1,221,596
2023$857,770$-$43,000$-$-$-$900,770
(1)Represents the grant date fair value of the equity awards to our NEOs other than our PEOs, as reported in the SCT.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.